An interventional study of Romiplostim (formerly AMG 531) in Hematology, MDS and Myelodysplastic Syndromes, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-29.
Sponsored by Amgen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one is the 5th largest by enrollment, is the only one that started in 2007, is the only one with no phase, and was the 5th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2007.
This study's enrollment of 72 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 72 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label extension study of romiplostim for treatment of thrombocytopenia (platelet count ≤ 50 x 10\^9/L) in MDS subjects. The study is designed to assess the long-term safety of treatment with romiplostim, as measured by incidence of overall adverse events, the incidence of bleeding events, the utilization of platelet transfusions, and the duration of platelet response. The study will further describe the time to disease progression to acute myeloid leukemia (AML) and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Romiplostim (formerly AMG 531)
Subjects will begin the study at an initial dose of 750 µg. Except for: * Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response. * Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count.
Overall Summary of Adverse Events
Time frame: During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks .
Incidence of Antibody (AB) Formation
Time frame: During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks.
Weekly Bleeding Events Per 100 Subject Years
During the time since the first dose of IP to the end of the treatment period. A single bleeding event was defined as each individual bleeding episode that originated from a specific organ system (eg, gastrointestinal system or central nervous system). A bleeding event that continued for more than 7 days was counted as separate events every eighth day.
Time frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.
Platelet Transfusion Events Per 100 Subject Years
During the time since the first dose of IP to the end of the treatment period. A discrete platelet transfusion event was defined as any number of platelet transfusions administered within a 3-day period. Platelet transfusions administered more than 3 days apart were counted as separate platelet transfusion events.
Time frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.
Weeks With Platelet Response Per Year
During the time since the first dose of IP to the end of the treatment period. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.
Time frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.
Time to First Platelet Response
Time since first dose of IP to the first platelet response. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.
Time frame: During treatment period. The average duration of romiplostim exposure is 56 weeks.
Duration of Platelet Response
Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.
Time frame: During treatment period. The average duration of romiplostim exposure is 56 weeks.
This study was available to subjects who completed a previous romiplostim study for the treatment of thrombocytopenia in subjects with low or intermediate-1 risk MDS. First Subject Enrolled: 17-Jul-2007; Last Subject Enrolled: 15-Feb-2011
| Milestone | Romiplostim |
|---|---|
| Started | 72 |
| Completed | 0 |
| Not completed | 72 |
| Withdrew: Progression of therapy-related mds | 1 |
| Withdrew: Protocol specified criteria | 7 |
| Withdrew: Administrative decision | 37 |
| Withdrew: Death | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Disease progression | 4 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Adverse event | 6 |
| Withdrew: Requirement for alternative therapy | 7 |
| Participant | Romiplostim |
|---|---|
| Subjects Reporting Any AE | 71 |
| Subjects Reporting Any Treatment-related AE | 19 |
| Subjects Reporting Any Treat-related Serious AE | 4 |
| Subjects Reporting Any Serious AE | 29 |
| Subjects Withdrew Study or Stop IP Due to AE | 8 |
During the time since the first dose of IP to the end of the treatment period. A single bleeding event was defined as each individual bleeding episode that originated from a specific organ system (eg, gastrointestinal system or central nervous system). A bleeding event that continued for more than 7 days was counted as separate events every eighth day.
| Events/100 subject-year | Romiplostim |
|---|---|
| Weekly Bleeding Events Per 100 Subject Years | 1120.5 (1047.1 to 1197.7) |
During the time since the first dose of IP to the end of the treatment period. A discrete platelet transfusion event was defined as any number of platelet transfusions administered within a 3-day period. Platelet transfusions administered more than 3 days apart were counted as separate platelet transfusion events.
| Events/100 subject-year | Romiplostim |
|---|---|
| Platelet Transfusion Events Per 100 Subject Years | 204.4 (173.8 to 238.9) |
During the time since the first dose of IP to the end of the treatment period. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.
| Weeks/Subject-year | Romiplostim |
|---|---|
| Weeks With Platelet Response Per Year | 34.6 (33.3 to 35.9) |
Time since first dose of IP to the first platelet response. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.
| Weeks | Romiplostim |
|---|---|
| Time to First Platelet Response | 2.3 (2.1 to 3.1) |
Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.
| Weeks | Romiplostim |
|---|---|
| Duration of Platelet Response | 20.0 ± 49.5 |
| Participant | Romiplostim |
|---|---|
| Positive binding AB to IP at or before baseline | 5 ± 94.7 |
| Neutralizing AB to IP at or before baseline | 0 |
| Binding AB positive to IP post-baseline only | 5 |
| Persistent binding AB positive to IP | 4 |
| Transient binding AB positive to IP | 1 |
| Positive binding AB to TPO at or before baseline | 4 |
| Neutralizing AB to TPO at or before baseline | 0 |
| Binding AB positive to TPO post-baseline only | 3 |
| Persistent binding AB positive to TPO | 2 |
| Transient binding AB positive to TPO | 1 |
Collected over The average duration is 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romiplostim | — | 29/72 (40.3%) | 66/72 (91.7%) |
| Event | Romiplostim |
|---|---|
| PneumoniaInfections and infestations | 3/72 |
| HaematomaVascular disorders | 3/72 |
| AnaemiaBlood and lymphatic system disorders | 2/72 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/72 |
| BronchitisInfections and infestations | 2/72 |
| Urinary tract infectionInfections and infestations | 2/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/72 |
| AnxietyPsychiatric disorders | 2/72 |
| HaematuriaRenal and urinary disorders | 2/72 |
| Renal failure acuteRenal and urinary disorders | 2/72 |
| Event | Romiplostim |
|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 23/72 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/72 |
| FatigueGeneral disorders | 15/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/72 |
| AnaemiaBlood and lymphatic system disorders | 13/72 |
| Abdominal painGastrointestinal disorders | 12/72 |
| ContusionInjury, poisoning and procedural complications | 12/72 |
| ConstipationGastrointestinal disorders | 11/72 |
| HeadacheNervous system disorders | 11/72 |
| HaematomaVascular disorders | 11/72 |
| Age, Continuous(Years) | Romiplostim |
|---|---|
| Mean | 68.9 ± 11.1 |
| Sex: Female, Male(Participants) | Romiplostim |
|---|---|
| Female | 32 |
| Male | 40 |
| Race/Ethnicity, Customized(Participant) | Romiplostim |
|---|---|
| White or Caucasian | 61 |
| Black or African American | 4 |
| Hispanic or Latino | 3 |
| Other | 4 |
| Myelodysplastic Syndromes World Health Organization Classification at Study Screening(Participants) | Romiplostim |
|---|---|
| RA: Refractory Anemia | 20 |
| RARS: Refractory Anemia with Ringed Sideroblasts | 1 |
| RAEB-1: Refractory Anemia with Excess Blasts-1 | 7 |
| RAEB-2: Refractory Anemia with Excess Blasts-2 | 2 |
| RCMD:Refractory cytopenia w multilineage dysplasia | 24 |
| RCMD-RS: RCMD and ringed sideroblasts | 3 |
| MDS-U: Myelodysplastic syndrome - unclassified | 15 |
| MDS associated with isolated del(5q) | 0 |
| Eastern Cooperative Oncology (ECOG) performance status(Participants) | Romiplostim |
|---|---|
| 0: Fully active | 42 |
| 1: Can carry out light or sedentary work | 25 |
| 2: Capable of selfcare but unable to work | 5 |
| >=3: Capable of only limited selfcare or worse | 0 |
| Baseline Platelet Count(10^9/L) | Romiplostim |
|---|---|
| Mean | 27.6 ± 15.5 |
No study locations are listed for this record.
Ran from Apr 2007 to primary completion in Jul 2011, 51 months.
Results were first posted in Jul 2013, 1 year 11 months after primary completion.
Of 58 interventional studies with no phase under Myelodysplastic Syndromes, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 125. This study's 51 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim